Cara Therapeutics Inc
Company Overview
Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics to treat pruritus (severe itching) in various patient populations. The company's lead product is KORSUVA (difelikefalin), which is approved for treating pruritus associated with chronic kidney disease in adults undergoing hemodialysis.
The company generates revenue primarily through product sales and licensing agreements related to its therapeutic developments. Their business model is based on developing and commercializing novel therapeutics, which is a halal business activity.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $2.56m | $14.78m | - | $1.96m | 0.00% | 13.26% |
| June 30, 2024 | $991000.0 | $20.21m | - | $1.91m | 0.00% | 9.45% |
| March 31, 2024 | $2.13m | $33.78m | - | $1.98m | 0.00% | 5.87% |
Company Impact
Help us evaluate Cara Therapeutics Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.